89bio to participate in the h.c. wainwright 7ᵗʰ annual nash investor conference

San francisco, oct. 17, 2023 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the company's management will participate in a fireside chat and one-on-one investor meetings at the h.c. wainwright 7th annual nash investor conference being held on tuesday, october 24, 2023.
ETNB Ratings Summary
ETNB Quant Ranking